Abstract:BackgroundWhile the frequency and importance of antipsychotic switching in patients with schizophrenia, there is insufficient evidence with regard to switching strategy. Quetiapine is one of the drugs of choice for switch because of its unique receptor profile. However, there were no data on the long-term clinical and neurocognitive effect of quetiapine in patients who had responded inadequately to prior antipsychotics. The purpose of this study is to examine the long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response. We hypothesized that quetiapine would show long-term effectiveness in broad symptom dimensions including negative and neurocognitive symptoms while having good tolerability.MethodsTwenty-nine subjects with schizophrenia who did not respond to their current monotherapy of antipsychotic or who could not tolerate the treatment were switched to quetiapine and assessed at baseline and at 3, 6, and 12 months. The outcome measures included the brief assessment of cognition in schizophrenia (BACS), the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), the Schizophrenia Quality of Life Scale Japanese version (JSQLS), the Athens Insomnia Scale (AIS), and the Drug Attitude Inventory with 30 items (DAI-30). The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), HbA1c, prolactin (PRL), and body weight were also evaluated.ResultsStatistically significant improvements were observed in all subscores of the PANSS, the GAF, and the symptoms and side effects subscale of the JSQLS, the DIEPSS, the AIS, and the PRL level, and nearly significant improvements were observed in the DAI-30. Quetiapine monotherapy was associated with significant improvement in the verbal memory test, even after controlling for the practice effect. Although quetiapine was well tolerated, three subjects dropped out because of the worsening of the psychotic symptoms and two additional subjects dropped out because of somnolence.ConclusionIn this open-label, single-arm study of 29 patients, quetiapine improved both the clinical symptoms and the neurocognitive impairment in chronic schizophrenia patients who failed to respond to prior antipsychotic treatment.

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Randomized controlled 16-week trial of the effect of quetiapine on the quality of life and cognitive functioning of patients in acute episodes of schizophrenia

Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.

EFFICACY AND TOLERABILITY OF QUETIAPINE XR 400/600/800MG/DAY IN ACUTE SCHIZOPHRENIA: A POST-HOC ANALYSIS OF DATA FROM TWO POOLED RANDOMISED STUDIES

A One-Year Follow-Up Study of 33 Female Schizophrenic Patients with Menstrual Disturbances after Switching to Quetiapine

Clinical study of quetiapine and clozapine in the treatment of schizophrenia

P03-242 - Efficacy and tolerability of quetiapine XR 400/600/800mg/day in acute schizophrenia: a post-hoc analysis of data from two pooled randomised studies

Comparisons of the Tolerability and Sensitivity of Quetiapine-Xr in the Acute Treatment of Schizophrenia, Bipolar Mania, Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study

Quetiapine and risperdal in the treatment of schizophrenia:an one-year follow up study.

A 6-Week, Multicenter, Double-Blind, Double-Dummy, Chlorpromazine-Controlled Non-Inferiorityrandomized Phase Iiitrial to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) in the Treatment of Patients with Schizophrenia and Acute Episodes.

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia

Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia

Switching from Olanzapine to Ziprasidone: a 12-Week, Open-Label, Multicenter Study Evaluating the Effectiveness and Safety of Ziprasidone in Patients with Schizophrenia.

A Randomized Double-Blind Controlled Study on the Efficacy of Quetiapine and Chlorpromazine in Treatment of Schizophrenia

Long‐term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta‐analysis

Effects Of Olanzapine, Quetiapine, And Risperidone On Neurocognitive Function In Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

Efficacy of Once-Daily Extended Release Quetiapine Fumarate Across Symptom Domains in Schizophrenia